Telix Pharmaceuticals announces licence agreement with Lilly for olaratumab
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Subscribe To Our Newsletter & Stay Updated